Speech-Language Pathologists in Mercerville, NJ Accepting Medicare

5 Speech-Language Pathologists found. Showing 1 - 5

John Rudy Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2240 Whitehorse Mercerville Rd, Mercerville, NJ 08619 Phone: 609-586-7500    Fax: 609-587-8619

Marilyn Greenberg, M.A.,CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9 Blue Devil Ln, Mercerville, NJ 08619 Phone: 609-586-5959    Fax: 609-586-5959

Ashley Sarrol, M.S. CCC-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 3100 Quakerbridge Road, Mercerville, NJ 08619 Phone: 609-584-7900    Fax: 609-631-6836

Kerri Pirrera Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 24 Coolidge Ave, Mercerville, NJ 08619 Phone: 609-203-2080

Mrs. Marlene Lee Stankus, M.A. CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 93 Terrapin Ln, Mercerville, NJ 08619 Phone: 609-577-5458

News Archive

Health law politics swirl around scandal reports, implementation frustrations

Some of the political ebb and flow is exactly as expected, with news reports noting that Rep. Michele Bachmann, R-Minn., a staunch opponent of the overhaul, is focused on linking the Internal Revenue Scandal with the health law.

When inequality pays dividends

When there are limited treatments for serious diseases, such as bird flu and HIV-AIDS, city residents should be first in line for the drugs ahead of those in rural areas to most effectively contain the risk to the community, according to research led by a University of New South Wales (UNSW) academic.

Quick-Med Technologies receives Notice of Allowance for MultiStat family of compounds

Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for intellectual property that extends the current patent coverage for the Company's MultiStat family of compounds. The forthcoming patent is part of a portfolio that Quick-Med has licensed from the University of Michigan.

New treatment improves visual acuity score of patients with retinitis pigmentosa

Neurotech SA announced positive results from an open-label Phase I clinical trial (03-EI-0234) of its lead product, NT-501. NT-501 uses Neurotech's patented Encapsulated Cell Technology (ECT) as a device to deliver ciliary neurotrophic factor (CNTF) to eyes of visually impaired patients with retinitis pigmentosa (RP). Neurotech is a biotechnology company specializing in the development of novel therapeutics to treat diseases of the eye. The company is headquartered in Paris.

Increased signaling by sonic hedgehog protein can inhibit LID in Parkinson's patients

Levodopa, or L-dopa, is considered the most effective treatment for Parkinson's disease today. After a few years of treatment, however, almost all patients develop a debilitating side-effect called L-dopa induced dyskinesia, or LID, which causes involuntary movements in the limbs, face, and torso. Deep brain stimulation can alleviate LID, but the procedure is highly invasive and not all patients are eligible.

Read more Medical News

› Verified 2 days ago